Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant glioma

Acta Histochemica

Volumn 114, Issue 5, 2012, Pages 503-509

  Cheng, Mao Wei ^a   Wang, Bing Chan ^b   Weng, Zhi Qiang ^a   Zhu, Xiao Wei ^a  

^a NANJING UNIVERSITY   (China)

^b MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Chemoradioresistance; Glioma; Polo like kinase 1; Prognosis; RNA interference; RT PCR

Indexed keywords

MESSENGER RNA; POLO LIKE KINASE 1;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; ENZYME INHIBITION; FEMALE; GENE; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; POLO LIKE KINASE 1 GENE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RADIOSENSITIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; CELL CYCLE PROTEINS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; YOUNG ADULT;

EID: 84860384540     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2011.09.004     Document Type: Article

References (30)

1. Chen X.H., Lan B., Qu Y., Zhang X.Q., Cai Q., Liu B.Y., et al. Inhibitory effect of Polo-like kinase 1 depletion on mitosis and apoptosis of gastric cancer cells. World J Gastroenterol 2006, 12:29-35.
2. Feng Y.B., Lin D.C., Shi Z.Z., Wang X.C., Shen X.M., Zhang Y., et al. Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma. Int J Cancer 2009, 124:578-588.
3. Gerster K., Shi W., Ng B., Yue S., Ito E., Waldron J., et al. Targeting Polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2010, 77:253-260.
4. Glover D.M., Hagan I.M., Tavares A.A. Polo-like kinases: a team that plays throughout mitosis. Genes Dev 1998, 12:3777-3787.
5. Gray P.J., Bearss D.J., Han H., Nagle R., Tsao M.S., Dean N., et al. Identification of human Polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol Cancer Ther 2004, 3:641-646.
6. He Z.L., Zheng H., Lin H., Miao X.Y., Zhong D.W. Overexpression of Polo-like kinase 1 predicts a poor prognosis in hepatocellular carcinoma patients. World J Gastroenterol 2009, 15:4177-4182.
7. Ito Y., Miyoshi E., Sasaki N., Kakudo K., Yoshida H., Tomoda C., et al. Polo-like kinase 1 overexpression is an early event in the progression of papillary carcinoma. Br J Cancer 2004, 90:414-418.
8. Jang Y.J., Kim Y.S., Kim W.H. Oncogenic effect of Polo-like kinase 1 expression in human gastric carcinomas. Int J Oncol 2006, 29:589-594.
9. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
10. Kanaji S., Saito H., Tsujitani S., Matsumoto S., Tatebe S., Kondo A., et al. Expression of Polo-like kinase 1 (PLK1) protein predicts the survival of patients with gastric carcinoma. Oncology 2006, 70:126-133.
11. Kneisel L., Strebhardt K., Bernd A., Wolter M., Binder A., Kaufmann R. Expression of Polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol 2002, 29:354-358.
12. Lan H., Zhu J., Ai Q., Yang Z., Ji Y., Hong S., et al. Rapid functional screening of effective siRNAs against Plk1 and its growth inhibitory effects in laryngeal carcinoma cells. BMB Rep 2010, 43:818-823.
13. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114:97-109.
14. Pellegrino R., Calvisi D.F., Ladu S., Ehemann V., Staniscia T., Evert M., et al. Oncogenic and tumor suppressive roles of Polo-like kinases in human hepatocellular carcinoma. Hepatology 2010, 51:857-868.
15. Reagan-Shaw S., Ahmad N. Silencing of Polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer. FASEB J 2005, 19:611-613.
16. Rödel F., Keppner S., Capalbo G., Bashary R., Kaufmann M., Rödel C., et al. Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer. Am J Pathol 2010, 177:918-929.
17. Smith M.R., Wilson M.L., Hamanaka R., Chase D., Kung H., Longo D.L., et al. Malignant transformation of mammalian cells initiated by constitutive expression of the Polo-like kinase. Biochem Biophys Res Commun 1997, 234:397-405.
18. Spänkuch B., Heim S., Kurunci-Csacsko E., Lindenau C., Yuan J., Kaufmann M., et al. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo. Cancer Res 2006, 66:5836-5846.
19. Takahashi T., Sano B., Nagata T., Kato H., Sugiyama Y., Kunieda K., et al. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 2003, 94:148-152.
20. Takai N., Hamanaka R., Yoshimatsu J., Miyakawa I. Polo-like kinases (Plks) and cancer. Oncogene 2005, 24:287-291.
21. Tyagi S., Bhui K., Singh R., Singh M., Raisuddin S., Shukla Y. Polo-like kinase 1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73α in p53 mutant human epidermoid squamous carcinoma cells. Biochem Pharmacol 2010, 80:1326-1334.
22. Wang R., Wang J.H., Chu X.Y., Geng H.C., Chen L.B. Expression of STK15 mRNA in hepatocellular carcinoma and its prognostic significance. Clin Biochem 2009, 42:641-647.
23. Weichert W., Schmidt M., Gekeler V., Denkert C., Stephan C., Jung K., et al. Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate 2004, 60:240-245.
24. Weichert W., Schmidt M., Jacob J., Gekeler V., Langrehr J., Neuhaus P., et al. Overexpression of Polo-like kinase 1 is a common and early event in pancreatic cancer. Pancreatology 2005, 5:259-265.
25. Weichert W., Kristiansen G., Schmidt M., Gekeler V., Noske A., Niesporek S., et al. Polo-like kinase 1 expression is a prognostic factor in human colon cancer. World J Gastroenterol 2005, 11:5644-5650.
26. Weichert W., Kristiansen G., Winzer K.J., Schmidt M., Gekeler V., Noske A., et al. Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications. Virchows Arch 2005, 446:442-450.
27. Weichert W., Denkert C., Schmidt M., Gekeler V., Wolf G., Köbel M., et al. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer 2004, 90:815-821.
28. Weitzer S., Uhlmann F. Chromosome segregation: playing polo in prophase. Dev Cell 2002, 2:381-382.
29. Xie S., Xie B., Lee M.Y., Dai W. Regulation of cell cycle checkpoints by Polo-like kinases. Oncogene 2005, 24:277-286.
30. Yamamoto Y., Matsuyama H., Kawauchi S., Matsumoto H., Nagao K., Ohmi C., et al. Overexpression of Polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer. Oncology 2006, 70:231-237.